pEGFP-N1 Vector Information PT3027-5

GenBank Accession #U55762 Catalog #6085-1

Ase I
(8)
ApaL I Sna B I
(341)
(4362)
MCS
(591–671)
PCMV IE
pUC
EcoO109 I ori
(3856)

HSV TK
poly A EGFP
pEGFP-N1
4.7 kb BsrG I (1389)
r SV40
Kan /
poly A
Not I (1402)
r
Neo
f1
Xba I* (1412)
SV40 ori
PSV40 P ori
e
Afl II (1640)
Dra III (1874)
Stu I
(2579)

591 601 611 621 631 641 651 661 671

EGFP
• • • • • • • • •
G CTA GCG CTA CCG GAC TCA GAT CTC GAG CTC AAG CTT CGA ATT CTG CAG TCG ACG GTA CCG CGG GCC CGG GAT CCA CCG GTC GCC ACC ATG GTG
Nhe I Eco47 III Bgl II Xho I Hind III EcoR I Pst I Sal I Kpn I Apa I BamH I Age I
Sac I Acc I Asp718 I Bsp120 I Xma I
Ecl136 II Sac II Sma I

Restriction Map and Multiple Cloning Site (MCS) of pEGFP-N1 Vector. All restriction sites shown are unique. The Not I
site follows the EGFP stop codon. The Xba I site (*) is methylated in the DNA provided by BD Biosciences Clontech. If you
wish to digest the vector with this enzyme, you will need to transform the vector into a dam– and make fresh DNA.

Description
pEGFP-N1 encodes a red-shifted variant of wild-type GFP (1–3) which has been optimized for
brighter fluorescence and higher expression in mammalian cells. (Excitation maximum = 488 nm;
emission maximum = 507 nm.) pEGFP-N1 encodes the GFPmut1 variant (4) which contains the
double-amino-acid substitution of Phe-64 to Leu and Ser-65 to Thr. The coding sequence of the
EGFP gene contains more than 190 silent base changes which correspond to human codon-usage
preferences (5). Sequences flanking EGFP have been converted to a Kozak consensus translation
initiation site (6) to further increase the translation efficiency in eukaryotic cells. The MCS in
pEGFP-N1 is between the immediate early promoter of CMV (PCMV IE) and the EGFP coding
sequences. Genes cloned into the MCS will be expressed as fusions to the N-terminus of EGFP if
they are in the same reading frame as EGFP and there are no intervening stop codons. SV40
polyadenylation signals downstream of the EGFP gene direct proper processing of the 3' end of the
EGFP mRNA. The vector backbone also contains an SV40 origin for replication in mammalian cells
expressing the SV40 T antigen. A neomycin-resistance cassette (Neor), consisting of the SV40 early
promoter, the neomycin/kanamycin resistance gene of Tn5, and polyadenylation signals from the
Herpes simplex virus thymidine kinase (HSV TK) gene, allows stably transfected eukaryotic cells to
be selected using G418. A bacterial promoter upstream of this cassette expresses kanamycin
resistance in E. coli. The pEGFP-N1 backbone also provides a pUC origin of replication for
propagation in E. coli and an f1 origin for single-stranded DNA production.

(PR29972; published 03 October 2002)

pEGFP-N1 Vector Information

Use
Fusions to the N terminus of EGFP retain the fluorescent properties of the native protein allowing the localization of
the fusion protein in vivo . The target gene should be cloned into pEGFP-N1 so that it is in frame with the EGFP coding
sequences, with no intervening in-frame stop codons. The inserted gene should include the initiating ATG codon. The
recombinant EGFP vector can be transfected into mammalian cells using any standard transfection method. If
required, stable transformants can be selected using G418 (7). pEGFP-N1 can also be used simply to express EGFP
in a cell line of interest (e.g., as a transfection marker).
Location of features
• Human cytomegalovirus (CMV) immediate early promoter: 1–589
Enhancer region:59–465; TATA box: 554–560
Transcription start point: 583
C→G mutation to remove Sac I site: 569
• MCS: 591–671
• Enhanced green fluorescent protein (EGFP) gene
Kozak consensus translation initiation site: 672–682
Start codon (ATG): 679–681; Stop codon: 1396–1398
Insertion of Val at position 2: 682–684
GFPmut1 chromophore mutations (Phe-64 to Leu; Ser-65 to Thr): 871–876
His-231 to Leu mutation (A→T): 1373
• SV40 early mRNA polyadenylation signal
Polyadenylation signals: 1552–1557 & 1581–1586; mRNA 3' ends: 1590 & 1602
• f1 single-strand DNA origin: 1649–2104 (Packages the noncoding strand of EGFP.)
• Bacterial promoterfor expression of Kanr gene:
–35 region: 2166–2171; –10 region: 2189–2194
Transcription start point: 2201
• SV40 origin of replication: 2445–2580
• SV40 early promoter
Enhancer (72-bp tandem repeats): 2278–2349 & 2350–2421
21-bp repeats: 2425–2445, 2446–2466 & 2468–2488
Early promoter element: 2501–2507
Major transcription start points: 2497, 2535, 2541 & 2546
• Kanamycin/neomycin resistance gene
Neomycin phosphotransferase coding sequences: start codon (ATG): 2629–2631; stop codon: 3421–3423
G→A mutation to remove Pst I site: 2811
C→A (Arg to Ser) mutation to remove BssH II site: 3157
• Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
Polyadenylation signals: 3659–3664 & 3672–3677
• pUC plasmid replication origin: 4008–4651

Primer Locations
• EGFP-N Sequencing Primer (#6479-1): 745–724
• EGFP-C Sequencing Primer (#6478-1): 1332–1353

Propagation in E. coli
• Suitable host strains: DH5a, HB101 and other general purpose strains. Single-stranded DNA production requires
a host containing an F plasmid such as JM101 or XL1-Blue.
• Selectable marker: plasmid confers resistance to kanamycin (30 µg/ml) to E. coli hosts.
• E. coli replication origin: pUC
• Copy number: ≈500
• Plasmid incompatibility group: pMB1/ColE1

References:
1. Prasher, D. C., et al. (1992) Gene 111:229–233.
2. Chalfie, M., et al. (1994) Science 263:802–805.
3. Inouye, S. & Tsuji, F. I. (1994) FEBS Letters 341:277–280.
4. Cormack, B., et al. (1996) Gene 173:33–38.
5. Haas, J., et al. (1996) Curr. Biol. 6:315–324.
6. Kozak, M. (1987) Nucleic Acids Res. 15:8125–8148.
7. Gorman, C. (1985). In DNA cloning: A practical approach, vol. II. Ed. D.M. Glover. (IRL Press, Oxford, U.K.) pp. 143–190.

BD Biosciences Clontech www.bdbiosciences.com Protocol # PT3027-5

2 Version # PR29972
pEGFP-N1 Vector Information

Note: The attached sequence file has been compiled from information in the sequence databases, published
literature, and other sources, together with partial sequences obtained by BD Biosciences Clontech. This vector has
not been completely sequenced.

Notice to Purchaser
Use of BD Biosciences Clontech’s Living Colors™ products containing DNA sequences coding for mutant Aequorea victoria green fluorescent
protein (GFP) variants or proteins thereof requires a license from Amersham Biosciences under U.S. Patent Nos. 5,625,048; 5,777,079; 6,054,321
and other pending U.S. and foreign patent applications. In addition, certain BD Biosciences Clontech products are made under U.S. Patent No.
5,804,387 licensed from Stanford University.
Not-For-Profit research institutes or entities are granted an automatic license with the purchase of this product for use in non-commercial internal
research purposes, the terms of which are disclosed in detail in the license that accompanies the shipment of this product. Such license specifi-
cally excludes the right to sell or otherwise transfer this product or its components to third parties.
For-Profit research institutes or entities must obtain a license from Amersham Biosciences. E-mail: gfp@amershambiosciences.com
Please contact BD Biosciences Clontech directly for any other assistance, including purchasing and technical support. All companies and
institutions purchasing Living Colors™ products will be included in a quarterly report to Aurora Biosciences, as required by the BD Biosciences
Clontech/Aurora Biosciences license agreement.
This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes nor is it intended for human
use. BD Biosciences Clontech products may not be resold, modified for resale, or used to manufacture commercial products without written
approval of BD Biosciences Clontech.

© 2002, Becton, Dickinson and Company

Protocol # PT3027-5 www.bdbiosciences.com BD Biosciences Clontech

Version # PR29972 3